<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="chapter-article"><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><?noissn?><front><journal-meta><journal-id journal-id-type="publisher-id">978-981-15-4814-7</journal-id><journal-id journal-id-type="doi">10.1007/978-981-15-4814-7</journal-id><journal-id journal-id-type="nlm-ta">Coronavirus Disease 2019 (COVID-19)</journal-id><journal-title-group><journal-title>Coronavirus Disease 2019 (COVID-19)</journal-title><journal-subtitle>Epidemiology, Pathogenesis, Diagnosis, and Therapeutics </journal-subtitle></journal-title-group><isbn publication-format="print">978-981-15-4813-0</isbn><isbn publication-format="electronic">978-981-15-4814-7</isbn></journal-meta><article-meta><article-id pub-id-type="pmcid">7189400</article-id><article-id pub-id-type="publisher-id">10</article-id><article-id pub-id-type="doi">10.1007/978-981-15-4814-7_10</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Therapeutic Development and Drugs for the Treatment of COVID-19</article-title></title-group><contrib-group content-type="book editors"><contrib contrib-type="editor"><name><surname>Saxena</surname><given-names>Shailendra K.</given-names></name><address><email>myedrsaxena@gmail.com</email></address><xref ref-type="aff" rid="Aff2"/></contrib><aff id="Aff2"><institution-wrap><institution-id institution-id-type="GRID">grid.411275.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 0645 6578</institution-id><institution>Centre for Advanced Research, </institution><institution>King George&#x02019;s Medical University, </institution></institution-wrap>Lucknow, India </aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Maurya</surname><given-names>Vimal K.</given-names></name><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Kumar</surname><given-names>Swatantra</given-names></name><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Bhatt</surname><given-names>Madan L. B.</given-names></name><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2856-4185</contrib-id><name><surname>Saxena</surname><given-names>Shailendra K.</given-names></name><address><email>shailen@kgmcindia.edu</email></address><xref ref-type="aff" rid="Aff3"/></contrib><aff id="Aff3"><institution-wrap><institution-id institution-id-type="GRID">grid.411275.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 0645 6578</institution-id><institution>Department of Centre for Advanced Research (CFAR), Faculty of Medicine, </institution><institution>King George&#x02019;s Medical University (KGMU), </institution></institution-wrap>Lucknow, India </aff></contrib-group><pub-date pub-type="epub"><day>30</day><month>04</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><fpage>109</fpage><lpage>126</lpage><permissions><copyright-statement>&#x000a9; The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd. 2020</copyright-statement><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">SARS-CoV-2/novel coronavirus (2019-nCoV) is a new strain that has recently been confirmed in Wuhan City, Hubei Province of China, and spreads to more than 165 countries of the world including India. The virus infection leads to 245,922 confirmed cases and 10,048 deaths worldwide as of March 20, 2020. Coronaviruses (CoVs) are lethal zoonotic viruses, highly pathogenic in nature, and responsible for diseases ranging from common cold to severe illness such as Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS) in humans for the past 15&#x000a0;years. Considering the severity of the current and previous outbreaks, no approved antiviral agent or effective vaccines are present for the prevention and treatment of infection during the epidemics. Although, various molecules have been shown to be effective against coronaviruses both in vitro and in vivo, but the antiviral activities of these molecules are not well established in humans. Therefore, this chapter is planned to provide information about available treatment and preventive measures for the coronavirus infections during outbreaks. This chapter also discusses the possible role of supportive therapy, repurposing drugs, and complementary and alternative medicines for the management of coronaviruses including COVID-19.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>SARS-CoV-2</kwd><kwd>Novel coronavirus (2019-nCoV)</kwd><kwd>MERS-CoV</kwd><kwd>SARS-CoV</kwd><kwd>Complementary and alternative medicines</kwd><kwd>Repurposing drugs</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd. 2020</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">Coronaviruses (CoVs) are enveloped, positive-sense RNA viruses belonging to the subfamily <italic>Coronavirinae</italic> and order <italic>Nidovirales</italic> (Huang et al. <xref ref-type="bibr" rid="CR25">2020</xref>). CoVs have a common genome organization and are commonly categorized as alpha CoVs, beta CoVs, gamma CoVs, and delta CoVs on the basis of genomic structures and phylogenetic relationships. In these CoVs, transmission of alpha CoVs and beta CoVs is restricted to mammals and induces respiratory illness in humans, while gamma CoVs and delta CoVs are known to affect birds and mammals (Song et al. <xref ref-type="bibr" rid="CR51">2019</xref>). Even though, most CoV infections are mild, but the outbreaks of the two beta CoVs, i.e., Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV), have caused more than 10,000 combined cases and 1600 deaths in last 20&#x000a0;years (Skariyachan et al. <xref ref-type="bibr" rid="CR50">2019</xref>). The incubation period of MERS and SARS is given as 2&#x02013;13 and 2&#x02013;14&#x000a0;days, respectively, the progression of infection is rapid with MERS-CoV as compared to SARS-CoV, and the reported mortality rates were 34% and 10%, respectively (Chen et al. <xref ref-type="bibr" rid="CR13">2020</xref>; Rasmussen et al. <xref ref-type="bibr" rid="CR43">2016</xref>). CoVs are zoonotic in nature, which means these viruses are transmitted between animals and humans. In the same way, SARS and MARS were reported to transmit in humans from civet cats and camel, respectively (Shehata et al. <xref ref-type="bibr" rid="CR49">2016</xref>). Human-to-human transmission of SARS and MARS is also reported via close personal contact with infected patients. In 2012, MERS emerged as global heath challenge in countries near the Arabian Peninsula. As of July 31, 2019, 2458 laboratory-confirmed MERS cases and 848 deaths were reported where around 80% of these cases have been reported only in Saudi Arabia (Zheng et al. <xref ref-type="bibr" rid="CR64">2019</xref>). In 2003, SARS-CoV was originated in southern China and transmitted to Hong Kong and 29 other countries with high human morbidity, leading to 8098 confirmed cases and 774 deaths (Hui and Zumla <xref ref-type="bibr" rid="CR26">2019</xref>).</p><p id="Par3">SARS-CoV-2 has recently been confirmed in Wuhan City, Hubei Province of China, and spreads to more than 165 countries of the world including India (Li et al. <xref ref-type="bibr" rid="CR35">2020</xref>). The virus infection leads to 245,922 confirmed cases and 10,048 deaths worldwide as of March 20, 2020 (ProMED-mail <xref ref-type="bibr" rid="CR42">2020</xref>). SARS-CoV-2 and SARS are clinically similar, and recent studies have shown that SARS-CoV-2 is closely related to SARS-CoV (Kumar et al. <xref ref-type="bibr" rid="CR31">2020</xref>). The cause and spread of SARS-CoV-2 outbreak are still unclear. Preliminary research has found positive samples for WN-CoV in the wholesale market of Huanan seafood in Wuhan City, but some patients confirmed by the laboratory have not reported visiting this area (Centers for Diseases Control and Prevention (CDC) <xref ref-type="bibr" rid="CR10">2020</xref>). Evidence is still emerging; however, information to date shows that transmission from human to human occurs. SARS-CoV-2 infection in patients leads to pneumonia-like symptoms such as fever and difficulty in breathing with radiographs showing invasive pneumonic infiltrates in few cases. The evolution of novel CoVs has been shown to be associated with RNA recombination with the existing CoVs (Andersen et al. <xref ref-type="bibr" rid="CR4">2020</xref>). The coronavirus (SARS-CoV-2, MERS, and SARS) infection initially spreads in adults, and the reported symptoms are fever, headache, vomiting, chills, dyspnea, nausea, sore throat, coughing up blood, shortness of breath, myalgia, diarrhea, and malaise (Table <xref rid="Tab1" ref-type="table">10.1</xref>). Severe infection leads to pneumonia, acute respiratory distress syndrome (ARDS), and sometimes multi-organ failure (Paules et al. <xref ref-type="bibr" rid="CR40">2020</xref>). Coronavirus infection leads to thrombocytopenia, lymphopenia, and leukopenia with elevated levels of lactate dehydrogenase and liver enzymes (Arabi et al. <xref ref-type="bibr" rid="CR5">2014</xref>).<table-wrap id="Tab1"><label>Table 10.1</label><caption><p>Epidemiology and characteristics of 2019-nCoV, MERS-CoV and SARS-CoV</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Characteristics</th><th>2019-nCoV</th><th>MERS-CoV</th><th>SARS-CoV</th></tr></thead><tbody><tr><td><italic>Genus</italic></td><td><italic>Beta-CoVs, lineage B</italic></td><td><italic>Beta-CoVs, lineage C</italic></td><td><italic>Beta-CoVs, lineage B</italic></td></tr><tr><td>Intermediary host</td><td>Malayan pangolins</td><td>Dromedary camel</td><td>Palm civet</td></tr><tr><td>Natural reservoir</td><td>Bat</td><td>Bat</td><td>Bat</td></tr><tr><td>Origin</td><td>Wuhan City, Hubei Province of China</td><td>Arabian Peninsula</td><td>Guangdong Province, China</td></tr><tr><td>Confirmed cases</td><td>245,922 (as of March 20, 2020)</td><td>2458 (July 31, 2019)</td><td>8098</td></tr><tr><td>Total deaths</td><td>10,048 (as of March 20, 2020)</td><td>848</td><td>774</td></tr><tr><td>Affected countries</td><td>168 (as of March 20, 2020)</td><td>27</td><td>29</td></tr><tr><td>Transmission patterns</td><td>From animal to human; from human to human</td><td>From animal to human; from human to human</td><td>From animal to human; from human to human</td></tr><tr><td>The predominant receptor</td><td>Cellular protease TMPRSS2 and angiotensin-converting enzyme 2</td><td>Human dipeptidyl peptidase 4 (DPP4 or CD26)</td><td>Human angiotensin-converting enzyme 2 (ACE2)</td></tr><tr><td>Cell line susceptibility</td><td>Respiratory tract</td><td>Respiratory tract, intestinal tract, genitourinary tract, liver, kidney, neurons, monocyte, T lymphocyte and histiocytic cell lines</td><td>Respiratory tract; kidney; liver</td></tr><tr><td>Viral replication efficiency</td><td>Very high</td><td>High</td><td>Lesser compared to MERS-CoV</td></tr><tr><td>Length of nucleotides</td><td>29,891</td><td>30,119</td><td>29,727</td></tr><tr><td>Open reading frames (ORFs)</td><td>12</td><td>11</td><td>11</td></tr><tr><td>Structural protein</td><td>4</td><td>4</td><td>4</td></tr><tr><td>Spike protein (length of amino acids)</td><td>1273</td><td>1353</td><td>1255</td></tr><tr><td>Non-structural proteins (NSPs)</td><td>16</td><td>16</td><td>5</td></tr><tr><td>Accessory proteins</td><td>6</td><td>5</td><td>8</td></tr><tr><td>A characteristic gene order</td><td>5&#x02032;-Replicase ORF1ab, spike (S), envelope (E), membrane (M), and nucleocapsid (N)-3&#x02032;</td><td>5&#x02032;-Replicase ORF1ab, spike (S), envelope (E), membrane (M), and nucleocapsid (N)-3&#x02032;</td><td>5&#x02032;-Replicase ORF1ab, spike (S), envelope (E), membrane (M), and nucleocapsid (N)-3&#x02032;</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec2"><title>Treatment of Novel Coronavirus SARS-CoV-2 Infection</title><p id="Par4">According to the World Health Organization (WHO), there is no existing data from randomized clinical trials to advocate any specific anti-nCoV therapy for patients either suspected or diagnosed with SARS-CoV-2. Unlicensed treatments can only be given in the circumstance of ethically approved clinical trials or under the Monitored Emergency Use of Unregistered Interventions System (MEURI), with strict supervision (World Health Organization <xref ref-type="bibr" rid="CR61">2020a</xref>). However, researchers have tested a number of FDA-approved drugs against SARS-CoV-2 infection, and these drugs have shown promising antiviral activity in both cell culture and animal models. Some of these drugs are also in clinical trial for SARS-CoV-2 (Li and De Clercq <xref ref-type="bibr" rid="CR33">2020</xref>). In the past 2&#x000a0;months, drugs from various classes such as nucleoside analogs, protease inhibitors, and host-targeted agents have been tested to discover an authorized antiviral agent against SARS-CoV-2 infection (Table <xref rid="Tab2" ref-type="table">10.2</xref>). The National Medical Products Administration of China has recently approved fapilavir as the first antiviral medication for the treatment of SARS-CoV-2.<table-wrap id="Tab2"><label>Table 10.2</label><caption><p>List of drugs that have antiviral activity compounds against SARS-CoV-2</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Antiviral agents</th><th>Drug targets</th><th>Reported mechanism of action</th></tr></thead><tbody><tr><td colspan="3"><italic>Virus-based treatment approaches</italic></td></tr><tr><td>Favipiravir</td><td>RdRp</td><td>Inhibits RdRp</td></tr><tr><td>Ribavirin</td><td>RdRp</td><td>Inhibits viral RNA synthesis and mRNA capping</td></tr><tr><td>Penciclovir</td><td>RdRp</td><td>Inhibits RdRp</td></tr><tr><td>Remdesivir (GS-5734)</td><td>RdRp</td><td>Terminates the non-obligate chain</td></tr><tr><td>Lopinavir</td><td>3CLpro</td><td>Inhibits 3CLpro</td></tr><tr><td>Ritonavir</td><td>3CLpro</td><td>Inhibits 3CLpro</td></tr><tr><td>Darunavir and cobicistat</td><td>3CLpro</td><td>Inhibits 3CLpro</td></tr><tr><td>ASC09F (HIV protease inhibitor)</td><td>3CLpro</td><td>Inhibits 3CLpro</td></tr><tr><td>Nafamostat</td><td>Spike glycoprotein</td><td>Inhibits spike-mediated membrane fusion</td></tr><tr><td>Griffithsin</td><td>Spike glycoprotein</td><td>Inhibits spike-mediated membrane fusion</td></tr><tr><td>Arbidol (umifenovir)</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td>Oseltamivir</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td colspan="3"><italic>Host-based treatment approaches</italic></td></tr><tr><td>Recombinant interferons</td><td>Interferon response</td><td>Exogenous interferons</td></tr><tr><td>Chloroquine</td><td>Endosomal acidification</td><td>A lysosomotropic base that appears to disrupt intracellular trafficking and viral fusion events</td></tr><tr><td>Nitazoxanide</td><td>Interferon response</td><td>Induces the host innate immune response to produce interferons by the host&#x02019;s fibroblasts and protein kinase R (PKR) activation</td></tr></tbody></table></table-wrap></p><sec id="Sec3"><title>Approved Nucleoside Analogs</title><p id="Par5">At present, two approved nucleoside analogs (ribavirin and favipiravir) demonstrated antiviral activity against SARS-CoV-2 infection (Wang et al. <xref ref-type="bibr" rid="CR56">2020</xref>). Nucleoside analogs have efficacy to target RNA-dependent RNA polymerase and inhibit the replication process in a broad range of RNA viruses including beta coronaviruses. Ribavirin was originally licensed for the treatment of HCV (hepatitis C virus) and RSV (respiratory syncytial virus). Ribavirin was also clinically evaluated against MERS and SARS coronaviruses, but the efficacy of the drug is uncertain and associated with severe side effects such as anemia and hypoxia at high doses (Arabi et al. <xref ref-type="bibr" rid="CR6">2019</xref>). Similarly, ribavirin was also evaluated against SARS-CoV-2 infection, but the antiviral property of drugs is still not well established against the SARS-CoV-2. In addition, after oral administration, the drug was rapidly absorbed via sodium-dependent nucleoside transporters into the gastrointestinal tract. The drug has oral bioavailability around 64% with large volume of distribution. Drugs such as acetaminophen, acetazolamide, aspirin, acrivastine, and acyclovir are known to decrease the excretion rate that leads to the higher serum level of ribavirin. Similarly, coadministration of abacavir may increase the hepatotoxicity of ribavirin. Favipiravir (T-705) was initially authorized for the treatment of influenza. In addition, it is reported that favipiravir is also effective against a number of RNA viruses such as Ebola, Nipah, and enterovirus. Similarly, favipiravir demonstrates efficacy against SARS-CoV-2, and currently the drug is in randomized trials with interferon-&#x003b1; and baloxavir marboxil for SARS-CoV-2 infection (Li and De Clercq <xref ref-type="bibr" rid="CR33">2020</xref>). The drug is well absorbed after oral administration in the gastrointestinal tract (98% bioavailability) and metabolized in liver, and the metabolites are excreted in urine. Favipiravir is contraindicated in pregnancy due to its teratogenic effect. Favipiravir also decreases the excretion of angiotensin-converting enzyme inhibitors such as captopril.</p></sec><sec id="Sec4"><title>Experimental Nucleoside Analogs</title><p id="Par6">Unlike the approved nucleoside analogs, two experimental nucleoside analogs remdesivir (GS-5734) and galidesivir (BCX4430) were also investigated against SARS-CoV-2 infection. Remdesivir and Galidesivir are adenine derivatives which demonstrate broad-spectrum antiviral activity in cell cultures and animal models against RNA viruses such as MERS and SARS (Agostini et al. <xref ref-type="bibr" rid="CR1">2018</xref>; Sheahan et al. <xref ref-type="bibr" rid="CR48">2020</xref>; Warren et al. <xref ref-type="bibr" rid="CR58">2014</xref>). Recently, it is shown that the drug inhibited SARS-CoV-2 by integrating into nascent viral RNA chains that lead to premature termination of viral RNA chains (Wang et al. <xref ref-type="bibr" rid="CR56">2020</xref>). Remdesivir is presently in clinical trial for Ebola and SARS-CoV-2 infection (Li and De Clercq <xref ref-type="bibr" rid="CR33">2020</xref>).</p></sec><sec id="Sec5"><title>Approved Protease Inhibitors</title><p id="Par7">Drugs such as disulfiram, lopinavir, and ritonavir have antiviral activity against human coronaviruses. Disulfiram was primarily used for the management of alcohol dependence, and it is reported that the drug also inhibits the papain-like protease of MERS and SARS in cell line models (Agostini et al. <xref ref-type="bibr" rid="CR1">2018</xref>). In addition, lopinavir and ritonavir are the HIV protease inhibitors that also have efficacy against 3-chymotrypsin-like protease of MERS and SARS (Sheahan et al. <xref ref-type="bibr" rid="CR48">2020</xref>; Kim et al. <xref ref-type="bibr" rid="CR29">2016</xref>; Chan et al. <xref ref-type="bibr" rid="CR11">2015</xref>). However, the mechanism of action of these protease inhibitors is still controversial. At present, lopinavir and ritonavir are in clinical trial in patients infected with SARS-CoV-2, and the results demonstrate that lopinavir&#x02013;ritonavir treatment fails to reduce mortality or throat viral RNA load in patients with Covid-19 (Cao et al. <xref ref-type="bibr" rid="CR9">2020</xref>). In the same way, nafamostat and griffithsin demonstrated inhibitory activity against spike glycoprotein of coronaviruses (Wang et al. <xref ref-type="bibr" rid="CR56">2020</xref>; Barton et al. <xref ref-type="bibr" rid="CR7">2014</xref>; O&#x02019;Keefe et al. <xref ref-type="bibr" rid="CR38">2010</xref>).</p></sec><sec id="Sec6"><title>Host-Targeted Strategies</title><p id="Par8">Several immune modulator drugs such as chloroquine, nitazoxanide, and ribavirin in combination of PEGylated interferon alfa-2a and -2b have shown inhibitory action against SARS-CoV-2 infection (Li and De Clercq <xref ref-type="bibr" rid="CR33">2020</xref>). A recent study has shown that chloroquine is more effective to prevent SARS-CoV-2 infection in cell culture model compared to other tested drugs and also in an open-label trial for the treatment of SARS-CoV-2 infection in patients (Fig. <xref rid="Fig1" ref-type="fig">10.1</xref>) (Wang et al. <xref ref-type="bibr" rid="CR56">2020</xref>).<fig id="Fig1"><label>Fig. 10.1</label><caption><p>Investigational treatment approaches for COVID-19 infection</p></caption><graphic xlink:href="498571_1_En_10_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec7"><title>Early Supportive Therapy for SARS-CoV-2 Infection</title><p id="Par9">Patients with severe acute respiratory infection should be closely monitored for clinical signs and symptoms like sepsis and rapid respiratory failure to provide immediate supportive treatment in case of severe infection. Supplemental oxygen therapy must be provided in case of shock, hypoxemia, severe acute respiratory infection, and respiratory distress. Similarly, fluid and electrolyte balance should be maintained in infected patients. Antimicrobial agents should be given for the management of pathogen-associated severe acute respiratory infections. The administration of systemic corticosteroids should be avoided in case of viral pneumonia and patients with acute respiratory distress syndrome (World Health Organization <xref ref-type="bibr" rid="CR62">2020b</xref>).</p></sec></sec><sec id="Sec8"><title>Treatment of MERS-CoV and SARS-CoV Infections</title><p id="Par10">In view of the high mortality rate of MERS-CoV and SARS-CoV infections, there are no licensed antiviral agents or vaccines available to date for successful disease control during outbreaks (Shahani et al. <xref ref-type="bibr" rid="CR47">2017</xref>). Although, various therapeutic alternatives have been given for the management of infection such as antiviral drugs (ribavirin, lopinavir, and ritonavir), convalescent plasma, corticosteroids, monoclonal antibodies, intravenous immunoglobulin, and repurposing of existing clinically FDA-approved drugs (Totura and Bavari <xref ref-type="bibr" rid="CR53">2019</xref>). The effectiveness of these drugs is not well established and given as symptomatic treatment to control the severity of infection. However, a retrospective analysis reported that ribavirin alone or in combination with interferon-alpha (IFN-&#x01f00;) or lopinavir or ritonavir showed increase in survival compared to patients taking supportive care and corticosteroids against MERS-CoV infection (Falzarano et al. <xref ref-type="bibr" rid="CR22">2013</xref>; Chu et al. <xref ref-type="bibr" rid="CR18">2004</xref>; Chiou et al. <xref ref-type="bibr" rid="CR16">2005</xref>; Loutfy et al. <xref ref-type="bibr" rid="CR36">2003</xref>). In the same way, several studies have reported that ribavirin in conjugation with fluoroquinolones and corticosteroids did not demonstrate efficacy in patients with SARS-CoV infection (Table <xref rid="Tab3" ref-type="table">10.3</xref>) (Al-Tawfiq et al. <xref ref-type="bibr" rid="CR3">2014</xref>; Omrani et al. <xref ref-type="bibr" rid="CR39">2014</xref>; Spanakis et al. <xref ref-type="bibr" rid="CR52">2014</xref>; Leong et al. <xref ref-type="bibr" rid="CR32">2004</xref>; Muller et al. <xref ref-type="bibr" rid="CR37">2007</xref>; Ward et al. <xref ref-type="bibr" rid="CR57">2005</xref>; Zhao et al. <xref ref-type="bibr" rid="CR63">2003</xref>). Nevertheless, it is concluded that ribavirin alone or in combination with other drugs fails to improve patient outcome against both MERS-CoV and SARS-CoV infections and is associated with adverse effects such as decreased hemoglobin levels, hemolytic anemia, hypoxemia, and metabolic abnormalities. In addition to ribavirin, interferons are also associated with psychiatric disturbances, neutropenia, and systemic adverse effects (Al-Dorzi et al. <xref ref-type="bibr" rid="CR2">2016</xref>). Drug repurposing is an eye-catching alternative approach for discovering newer drugs during the virus epidemics for a number of viral infections because various measures are typically skipped during the initial phase of drug design. Recently, researchers have investigated the antiviral potential of various approved drugs as first-line of defense against the newly emerging infectious agents. Repurposing of pharmaceutical agents could be an effective arm to develop potential therapeutics for SARS-CoV-2, MERS-CoV, and SARS-CoV infection (Dyall et al. <xref ref-type="bibr" rid="CR21">2017</xref>). The drugs from various classes such as antidiarrheal agents, antimalarial agents, cyclophilin inhibitors, interferons, kinase inhibitors, neurotransmitter inhibitors, anticholinergics, nucleic acid synthesis inhibitors, protease inhibitors, protein synthesis inhibitors, selective estrogen receptor modulators, and sterol metabolism inhibitors have demonstrated in vitro and in vivo antiviral efficacy against MERS-CoV and SARS-CoV infection (Table <xref rid="Tab4" ref-type="table">10.4</xref>) (Dyall et al. <xref ref-type="bibr" rid="CR20">2014</xref>, <xref ref-type="bibr" rid="CR21">2017</xref>; de Wilde et al. <xref ref-type="bibr" rid="CR59">2011</xref>, <xref ref-type="bibr" rid="CR60">2014</xref>; Hart et al. <xref ref-type="bibr" rid="CR23">2014</xref>; Cinatl et al. <xref ref-type="bibr" rid="CR19">2003</xref>; Kindrachuk et al. <xref ref-type="bibr" rid="CR30">2015</xref>; Cheng et al. <xref ref-type="bibr" rid="CR15">2015</xref>; Saijo et al. <xref ref-type="bibr" rid="CR44">2005</xref>; Zhou et al. <xref ref-type="bibr" rid="CR65">2015</xref>; Cao et al. <xref ref-type="bibr" rid="CR8">2015</xref>).<table-wrap id="Tab3"><label>Table 10.3</label><caption><p>Drug regimens used for the treatment of MERS and SARS-CoV infection</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Treatment</th><th>Outcome</th></tr></thead><tbody><tr><td colspan="2"><italic>MERS-CoV infection</italic></td></tr><tr><td><p>Ribavirin (oral/IV)</p><p>IFN-&#x01f00; 2b</p><p>Corticosteroids</p></td><td>Late treatment administration. Disease progression delayed and all patients died</td></tr><tr><td><p>Ribavirin (oral/IV)</p><p>PEGylated IFN-&#x01f00; (IV)</p><p>&#x000b1;&#x000a0;Corticosteroids</p></td><td><p>Treatment was given 0&#x02013;8&#x000a0;days after diagnosis</p><p>Significant decreases in hemoglobin and absolute neutrophil count (baseline count lower in treatment group) were also reported</p></td></tr><tr><td><p>Ribavirin (oral/IV)</p><p>Lopinavir/ritonavir</p><p>IFN-&#x01f00;-2b</p></td><td><p>No detectable viral RNA in serum after 2&#x000a0;days of therapy</p><p>Ribavirin discontinued due to jaundice, hyperbilirubinemia</p><p>Patients died with septic shock in 2&#x000a0;months</p></td></tr><tr><td colspan="2"><italic>SARS-CoV infection</italic></td></tr><tr><td><p>Ribavirin (oral/IV)</p><p>Antibiotics</p><p>&#x000b1;&#x000a0;Corticosteroids</p><p>&#x000b1;&#x000a0;Immunoglobulin</p></td><td><p>No increased positive outcome with ribavirin compared to controls</p><p>Increased risk of anemia, hypomagnesemia, hypoxia, or bradycardia with ribavirin compared to ribavirin-naive patients</p></td></tr><tr><td><p>Ribavirin (oral/IV)</p><p>Lopinavir/ritonavir</p><p>&#x000b1;&#x000a0;Corticosteroids</p></td><td>Fatality or acute respiratory distress syndrome (ARDS) was reduced significantly from 28.8% to 2.4%</td></tr><tr><td><p>IFN-alfacon-1</p><p>&#x000b1;&#x000a0;Corticosteroids</p><p>&#x000b1;&#x000a0;Antibiotics</p></td><td><p>Increased oxygen saturation</p><p>Increased clearance of lung abnormalities</p><p>Slight increase in creatinine kinase concentrations</p></td></tr><tr><td><p>Fluoroquinolone (IV)</p><p>Azithromycin (IV)</p><p>IFN-&#x003b1; (IM)</p><p>&#x000b1;&#x000a0;Corticosteroids</p><p>&#x000b1;&#x000a0;Immunoglobulins</p><p>&#x000b1;&#x000a0;Thymic peptides/proteins</p></td><td>No increased positive outcome</td></tr><tr><td><p>Quinolone (IV)</p><p>Azithromycin (IV)</p><p>&#x000b1;&#x000a0;IFN-&#x003b1;</p><p>&#x000b1;&#x000a0;Corticosteroids</p></td><td>No increased positive outcome</td></tr><tr><td><p>Levofloxacin</p><p>Azithromycin</p><p>&#x000b1;&#x000a0;IFN-&#x003b1;</p><p>&#x000b1;&#x000a0;Corticosteroids</p></td><td><p>Increased survival</p><p>Increased clearance of lung abnormalities</p></td></tr></tbody></table></table-wrap><table-wrap id="Tab4"><label>Table 10.4</label><caption><p>List of drugs with in vitro and in vivo antiviral activity against MERS-CoV and SARS-CoV</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Drugs</th><th>Class</th><th>Mechanism of action</th></tr></thead><tbody><tr><td>Loperamide</td><td>Antidiarrheal agents</td><td>Unknown</td></tr><tr><td>Chloroquine, amodiaquine, mefloquine</td><td>Antimalarial agents</td><td><p>Chloroquine targets the type II transmembrane serine protease of MERS-CoV</p><p>For SARS-CoV, chloroquine has also been attributed to a deficit in glycosylation of the receptor angiotensin-converting enzyme 2</p></td></tr><tr><td>Cyclosporine A</td><td>Cyclophilin inhibitors</td><td>Unknown</td></tr><tr><td>IFN-&#x01f00;, &#x003b2;1a, &#x003b3;, IFN-&#x01f00; 2b</td><td>Interferons</td><td>Inhibits replication of MERS-CoV and SARS-CoV</td></tr><tr><td>Imatinib, dasatinib, selumetinib, trametinib, sirolimus</td><td>Kinase inhibitors</td><td><p>Imatinib and dasatinib act as entry inhibitor for both MERS and SARS</p><p>Selumetinib and trametinib block the entry and replication of MERS-CoV via targeting ERK/MAPK signaling pathway. Sirolimus reduced MERS-CoV infection by ~60% via targeting mTOR signaling pathway</p></td></tr><tr><td>Chlorpromazine, triflupromazine, thiethylperazine, promethazine fluphenazine, astemizole, chlorphenoxamine, fluspirilene</td><td>Neurotransmitter inhibitors</td><td>Chlorpromazine inhibits virus entry, whereas antiviral mechanism of other listed drugs was still not clearly understood</td></tr><tr><td>Benztropine</td><td>Anticholinergic</td><td>Unknown</td></tr><tr><td>Ribavirin, mycophenolic acid, mizoribine, gemcitabine</td><td>Nucleic acid synthesis inhibitors</td><td>Unknown</td></tr><tr><td>Camostat mesylate, K11777, E-64-D, lopinavir</td><td>Protease inhibitors</td><td>Camostat mesylate inhibits TMPSSR2-mediated glycoprotein activation of MERS-CoV and SARS-CoV. K11777 and E-64-D act as attachment inhibitor for both MERS-CoV and SARS-CoV. Lopinavir has been shown to target the main protease (Mpro) of SARS-CoV</td></tr><tr><td>Emetine, anisomycin, omacetaxine mepesuccinate</td><td>Protein synthesis inhibitors</td><td>Unknown</td></tr><tr><td>Toremifene citrate, tamoxifen citrate</td><td>Selective estrogen receptor modulators</td><td>Unknown</td></tr><tr><td>Terconazole and triparanol</td><td>Sterol metabolism inhibitors</td><td>Unknown</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec9"><title>Vaccine for Coronaviruses</title><p id="Par11">Currently, vaccines that can protect against CoV infection are not available. Recently, many groups are involved in vaccine designing using a variety of platforms against CoVs. Some of these approaches have demonstrated effectiveness in animal models. The spike (S) protein present in CoVs acts as a viral antigen and responsible for host&#x02013;receptor binding and virus internalization and induces robust humoral and cell-mediated responses in humans during infection. The S glycoprotein has been shown to involve in the internalization of other CoVs like SARS by binding to its cellular receptor angiotensin-converting enzyme 2 (ACE2). The S-protein functions in the receptor binding and membrane fusion make it the ideal target for the production of vaccines against CoVs (Wang et al. <xref ref-type="bibr" rid="CR55">2016</xref>). Recent experiments have shown that the S-protein vaccine can trigger antibodies to resist virus binding, fusion, and neutralization of SARS-CoV infection. Recently, S-protein-based vaccines such as DNA vaccines, modified vaccinia Ankara (MVA)-based chimeric virus vaccines, subunit vaccines, and virus-like replicon particle (VRP)-based chimeric virus vaccines have been developed, and they demonstrate protective effect against both MERS-CoV and SARS-CoV infections in animal models (Schindewolf and Menachery <xref ref-type="bibr" rid="CR46">2019</xref>).</p></sec><sec id="Sec10"><title>Complementary and Alternative Medicines (CAM) for Coronaviruses</title><p id="Par12">According to the National Center for Complementary and Integrative Health (NCCIH) of the National Institute of Health (NIH), USA, CAM encompasses various medical methods, such as homeopathy, naturopathy, Ayurveda, medicinal systems, and products originating from traditional medicine. Recently, CAM therapies have shown to be potential therapeutics for the management of virus-associated diseases such as influenza, Japanese encephalitis, hepatitis C, zika, and HIV (Saxena et al. <xref ref-type="bibr" rid="CR45">2017</xref>). These medicines also demonstrate efficacy against coronaviruses with minimal reported adverse effects on host cells. Considering the global transmission and fatality rate of SARS-CoV-2 infection, the Government of India, Ministry of Ayush has given recommendations for the use of Indian herbal drugs that practices under the Ayurveda, Homeopathy, and Unani system of medicine for combating coronaviruses (PIB Delhi <xref ref-type="bibr" rid="CR41">2020</xref>).</p><sec id="Sec11"><title>Ayurverdic Medicines for the Treatment of Coronaviruses</title><p id="Par13">Shadanga Paniya is a herbal formulation that mainly comprises <italic>Cyperus rotundus</italic>, <italic>Fumaria indica</italic>, <italic>Vetiveria zizanioides</italic>, <italic>Pterocarpus santalinus</italic>, <italic>Pavonia odorata</italic>, and <italic>Zingiber officinale</italic>). This herbal formulation is recommended for the treatment of symptoms such as high fever, shivering, muscle aches, headache, loss of appetite, dehydration, fatigue, restlessness, excessive thirst, irritability, and burning sensation. In addition, Shadanga Paniya also has antibacterial and antimicrobial activities, and recently, this medicine is recommended by the Ministry of Ayush for the treatment of coronaviruses. Agastya Harityaki is a popular polyherbal Ayurverdic medicine mainly recommended for respiratory problems such as asthma, pneumonia, and chronic bronchitis. The medicine is reported to have antiviral, antibacterial, antifungal, antioxidant, anticarcinogenic, antiaging, antidiabetic, antiulcer, cardioprotective, hepatoprotective, and wound healing properties. Samshamani Vati is used for the treatment of acute to chronic fever and anemia (500&#x000a0;mg twice a day). <italic>Tinospora cordifolia</italic> is the main ingredient and responsible for anti-inflammatory and antipyretic properties of Samshamani Vati. Pratimarsha Nasya (Anu taila/sesame oil) has preventive as well as curative aspect for the treatment of Nasobronchial diseases and enhances the respiratory immunity. The ingredients present in sesame oil are well known for anti-inflammatory, antipyretic, and antibacterial proprieties. Another formulation which comprises Trikatu (Pippali, Marich, and Shunthi) and Tulasi is also recommended by the Ministry of Ayush for the treatment of coronavirus infection in India.</p></sec><sec id="Sec12"><title>Homeopathic Medicines for the Treatment of Coronaviruses</title><p id="Par14">After the emergence of SARS-CoV-2 in India, the Central Council for Research in Homeopathy (CCRH) has recommended Arsenicum Album 30 as prophylactic medicine against coronavirus infections. It was recommended that one dose of Arsenicum Album 30 should be given daily in empty stomach for 3&#x000a0;days and should be replicated after 1&#x000a0;month on the same schedule in the case of coronavirus infections arising in the population.</p></sec><sec id="Sec13"><title>Unani Medicines for the Treatment of Coronaviruses</title><p id="Par15">The Government of India has suggested a number of Unani medicines such as Sharbat Unnab (10&#x02013;20&#x000a0;ml), TiryaqArba (3&#x02013;5&#x000a0;g), TiryaqNazla (5&#x000a0;g), Habb e IkseerBukhar (2&#x000a0;pills), Sharbat Nazla (10&#x000a0;ml), and Qurs e Suaal (2 tablets) recommended twice a day with lukewarm water. In addition, Arq Ajeeb (4&#x02013;8 drops) and Khamira Marwareed (3&#x02013;5&#x000a0;g) are also suggested for the better management of disease. Similarly, medicines like RoghanBaboona/Roghan Mom/Kafoori Balm are also recommended for massage on scalp and chest in case of infection. In addition, the Arq extracted from single Unani drugs like <italic>Azadirachta indica</italic> (Margosa), <italic>Swertiachirata karst</italic> (Indian Gentian), <italic>Trachyspermum ammi sprague</italic> (ajowan), <italic>Cichorium intybus</italic> Linn. (common chicory), <italic>Cyperus scariosus</italic> R. Br. (cypriol), <italic>Borage officinalis</italic> Linn. (Borage), and <italic>Artemisia absinthium</italic> Linn. (common sagewort) along with SharbatKhaksi may be used to combat the infection. In the same way, decoction of Unani drugs such as <italic>Cydonia oblonga</italic> (Quince), <italic>Zizyphus Jujube</italic> Linn. (jujubi), Papaver somniferum (khashkhash), <italic>Cordia myxa</italic> Linn. (Assyrian plum), <italic>Cinnamomum zeylanicum</italic> (cinnamon), <italic>Hyoscyamus niger</italic> (bazrulbanj), <italic>Viola odorata</italic> Linn. (sweet violet), <italic>Borago Officinalis</italic> Linn. (borage), <italic>Myrtus communis</italic> (Barg e Moard), <italic>Lactuca sativa</italic> (Tukhm e kahuMukashar), and <italic>Rosa damascene</italic> (GuleSurkh) are also being suggested for conditions like sore throat during infection.</p></sec><sec id="Sec14"><title>Herbal Medicines Showing Efficacy Against Coronavirus in Cell Culture Model</title><p id="Par16">It is reported that a number of herbal extract of <italic>Anthemis hyaline</italic>, <italic>Acanthopanacis cortex</italic>, <italic>Citrus sinensis</italic>, <italic>Sophorae radix</italic>, <italic>Sanguisorbae radix</italic>, <italic>Nigella sativa</italic>, and <italic>Torilis fructus</italic> inhibit coronavirus replication in vitro (Ulasli et al. <xref ref-type="bibr" rid="CR54">2014</xref>; Kim et al. <xref ref-type="bibr" rid="CR28">2010</xref>). Similarly, studies have demonstrated that traditionally used medicinal herbal extracts such as <italic>Cimicifuga rhizoma</italic>, <italic>Coptidis rhizoma</italic>, <italic>Phellodendron cortex</italic>, and <italic>Meliae cortex</italic> are also shown to inhibit CoV replication in cell culture model (Kim et al. <xref ref-type="bibr" rid="CR27">2008</xref>). Emodin, a chemical constituent of genus Rheum, and Polygonum are also shown to block the binding of SARS-CoV S-protein to ACE2 in a dose-dependent manner (Ho et al. <xref ref-type="bibr" rid="CR24">2007</xref>). In the same manner, <italic>Artemisia annua</italic>, <italic>Lycoris radiate</italic>, <italic>Lindera aggregata</italic>, <italic>lycorine</italic>, and <italic>Pyrrosia lingua</italic> also showed antiviral activity against SARS-CoV (Li et al. <xref ref-type="bibr" rid="CR34">2005</xref>). In addition, saikosaponins are natural triterpene glycosides (A, B<sub>2</sub>, C, and D) and were tested against HCoV-22E9, and it is found that saikosaponin B<sub>2</sub> inhibits virus attachment and penetration stage to the host cells (Cheng et al. <xref ref-type="bibr" rid="CR14">2006</xref>). In the same way, myricetin and scutellarein act as inhibitor of SARS-CoV helicase. Similarly, theaflavin-3,3-digallate (TF3) is a natural polyphenolic compound and demonstrates antiviral activity via targeting 3C-like proteases of SARS-CoV (Chen et al. <xref ref-type="bibr" rid="CR12">2005</xref>). Eupatorium fortune is a herbal medicinal plant belonging to Korea, China, and Asian countries with antibacterial and antioxidant activities and anticancer activity. Recent studies have reported that eupatorium fortune can inhibit a number of RNA viruses including human coronaviruses (Choi et al. <xref ref-type="bibr" rid="CR17">2017</xref>). As these herbal drugs demonstrated potential antiviral activity against CoVs, there is an urgent need to establish their effectiveness in humans and approve in a dose-dependent manner from various organizations like Food and Drug Administration (FDA). In the absence of specific antiviral agent or vaccine, the use of complementary and alternative drugs may found to be beneficial during humanitarian emergencies.</p></sec></sec><sec id="Sec15"><title>Conclusions</title><p id="Par17">The recent outbreak brought SARS-CoV-2 as global concern and emphasizes the significance of restricting infectious agents at international borders. The risk of SARS-CoV-2 outbreaks depends on the characteristics of the virus, including the ability of the virus to transmit among humans, the seriousness of the disease, and the medical or other interventions available to prevent the transmission of virus, such as vaccines or drugs. Although, ribavirin along with corticosteroids and interferons has been tested in patients with SARS and MARS-CoV infections, but the effectiveness and associated severe adverse effects of this regimen is still not yet confirmed. In addition, a large number of drugs from different classes have been used for the management of symptoms associated with the infection and reported to have antiviral activity against both SARS and MARS-CoV infections in animal and cell culture model. However, the antiviral potential of these repurposing drugs are need to be validated in clinical trials in order to developed broad-spectrum therapy for SARS-CoV-2, SARS-CoV, and MARS-CoV infections.</p></sec><sec id="Sec16"><title>Future Perspectives</title><p id="Par18">At present, the control of viral spread is critical in order to restrict the transmission of infection. The effective communication among the various organizations such as government, industry, academic, national, and international bodies is crucial in order to prevent the transmission of infection during outbreaks. In the absence of specific therapeutic agent, the study of pathogenesis of infection is imperative to identify newer targets for designing of novel therapeutic agents for future outbreaks. Similarly, the standardization of various complementary and alternative medicines may prove as safe and potential therapeutic strategies for emerging CoVs.</p><sec id="FPar1"><title>Acknowledgements and Disclosures</title><p id="Par19">The authors are grateful to the Vice Chancellor, King George&#x02019;s Medical University (KGMU), Lucknow, India for the encouragement for this work. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.</p><p id="Par20"><italic>Financial support</italic>: None.</p><p id="Par21"><italic>Conflict of interest</italic>: The authors declare no conflict of interest.</p></sec></sec></body><back><ref-list id="Bib1"><title>References</title><ref id="CR1"><mixed-citation publication-type="other">Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, Smith EC, Case JB, Feng JY, Jordan R, Ray AS, Cihlar T, Siegel D, Mackman RL, Clarke MO, Baric RS, Denison MR (2018) Coronavirus susceptibility to the antiviral Remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading Exoribonuclease. MBio 9(2). pii: e00221-18. 10.1128/mBio.00221-18</mixed-citation></ref><ref id="CR2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Dorzi</surname><given-names>HM</given-names></name><name><surname>Alsolamy</surname><given-names>S</given-names></name><name><surname>Arabi</surname><given-names>YM</given-names></name></person-group><article-title>Critically ill patients with Middle East respiratory syndrome coronavirus infection</article-title><source>Crit Care</source><year>2016</year><volume>20</volume><fpage>65</fpage><pub-id pub-id-type="doi">10.1186/s13054-016-1234-4</pub-id><?supplied-pmid 26984370?><pub-id pub-id-type="pmid">26984370</pub-id></element-citation></ref><ref id="CR3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Tawfiq</surname><given-names>JA</given-names></name><name><surname>Momattin</surname><given-names>H</given-names></name><name><surname>Dib</surname><given-names>J</given-names></name><name><surname>Memish</surname><given-names>ZA</given-names></name></person-group><article-title>Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study</article-title><source>Int J Infect Dis</source><year>2014</year><volume>20</volume><fpage>42</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2013.12.003</pub-id><?supplied-pmid 24406736?><pub-id pub-id-type="pmid">24406736</pub-id></element-citation></ref><ref id="CR4"><mixed-citation publication-type="other">Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF (2020) The proximal origin of SARS-CoV-2. Nat Med:1&#x02013;3. 10.1038/s41591-020-0820-9</mixed-citation></ref><ref id="CR5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arabi</surname><given-names>YM</given-names></name><name><surname>Arifi</surname><given-names>AA</given-names></name><name><surname>Balkhy</surname><given-names>HH</given-names></name><name><surname>Najm</surname><given-names>H</given-names></name><name><surname>Aldawood</surname><given-names>AS</given-names></name><name><surname>Ghabashi</surname><given-names>A</given-names></name><name><surname>Hawa</surname><given-names>H</given-names></name><name><surname>Alothman</surname><given-names>A</given-names></name><name><surname>Khaldi</surname><given-names>A</given-names></name><name><surname>Al Raiy</surname><given-names>B</given-names></name></person-group><article-title>Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection</article-title><source>Ann Intern Med</source><year>2014</year><volume>160</volume><issue>6</issue><fpage>389</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.7326/M13-2486</pub-id><?supplied-pmid 24474051?><pub-id pub-id-type="pmid">24474051</pub-id></element-citation></ref><ref id="CR6"><mixed-citation publication-type="other">Arabi YM, Shalhoub S, Mandourah Y, Al-Hameed F, Al-Omari A, Al Qasim E, Jose J, Alraddadi B, Almotairi A, Al Khatib K, Abdulmomen A, Qushmaq I, Sindi AA, Mady A, Solaiman O, Al-Raddadi R, Maghrabi K, Ragab A, Al Mekhlafi GA, Balkhy HH, Al Harthy A, Kharaba A, Gramish JA, Al-Aithan AM, Al-Dawood A, Merson L, Hayden FG, Fowler R (2019. pii: ciz544. [Epub ahead of print]) Ribavirin and Interferon therapy for critically ill patients with Middle East Respiratory Syndrome: a multicenter observational study. Clin Infect Dis. 10.1093/cid/ciz544</mixed-citation></ref><ref id="CR7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barton</surname><given-names>C</given-names></name><name><surname>Kouokam</surname><given-names>JC</given-names></name><name><surname>Lasnik</surname><given-names>AB</given-names></name><name><surname>Foreman</surname><given-names>O</given-names></name><name><surname>Cambon</surname><given-names>A</given-names></name><name><surname>Brock</surname><given-names>G</given-names></name><name><surname>Montefiori</surname><given-names>DC</given-names></name><name><surname>Vojdani</surname><given-names>F</given-names></name><name><surname>McCormick</surname><given-names>AA</given-names></name><name><surname>O&#x02019;Keefe</surname><given-names>BR</given-names></name><name><surname>Palmer</surname><given-names>KE</given-names></name></person-group><article-title>Activity of and effect of subcutaneous treatment with the broad-spectrum antiviral lectin griffithsin in two laboratory rodent models</article-title><source>Antimicrob Agents Chemother</source><year>2014</year><volume>58</volume><issue>1</issue><fpage>120</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1128/AAC.01407-13</pub-id><?supplied-pmid 24145548?><pub-id pub-id-type="pmid">24145548</pub-id></element-citation></ref><ref id="CR8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>J</given-names></name><name><surname>Forrest</surname><given-names>JC</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name></person-group><article-title>A screen of the NIH clinical collection small molecule library identifies potential anti-coronavirus drugs</article-title><source>Antivir Res</source><year>2015</year><volume>114</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2014.11.010</pub-id><?supplied-pmid 25451075?><pub-id pub-id-type="pmid">25451075</pub-id></element-citation></ref><ref id="CR9"><mixed-citation publication-type="other">Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X, Xia J, Chen N, Xiang J, Yu T, Bai T, Xie X, Zhang L, Li C, Yuan Y, Chen H, Li H, Huang H, Tu S, Gong F, Liu Y, Wei Y, Dong C, Zhou F, Gu X, Xu J, Liu Z, Zhang Y, Li H, Shang L, Wang K, Li K, Zhou X, Dong X, Qu Z, Lu S, Hu X, Ruan S, Luo S, Wu J, Peng L, Cheng F, Pan L, Zou J, Jia C, Wang J, Liu X, Wang S, Wu X, Ge Q, He J, Zhan H, Qiu F, Guo L, Huang C, Jaki T, Hayden FG, Horby PW, Zhang D, Wang C (2020) A trial of Lopinavir-Ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 10.1056/NEJMoa2001282</mixed-citation></ref><ref id="CR10"><mixed-citation publication-type="other">Centers for Diseases Control and Prevention (CDC) (2020). <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/about/transmission.html">https://www.cdc.gov/coronavirus/2019-ncov/about/transmission.html</ext-link>. Accessed 15 Mar 2020</mixed-citation></ref><ref id="CR11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>JF</given-names></name><name><surname>Yao</surname><given-names>Y</given-names></name><name><surname>Yeung</surname><given-names>ML</given-names></name><name><surname>Deng</surname><given-names>W</given-names></name><name><surname>Bao</surname><given-names>L</given-names></name><name><surname>Jia</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Xiao</surname><given-names>C</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>P</given-names></name><name><surname>Cai</surname><given-names>JP</given-names></name><name><surname>Chu</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Qin</surname><given-names>C</given-names></name><name><surname>Yuen</surname><given-names>KY</given-names></name></person-group><article-title>Treatment with Lopinavir/Ritonavir or Interferon-&#x003b2;1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset</article-title><source>J Infect Dis</source><year>2015</year><volume>212</volume><issue>12</issue><fpage>1904</fpage><lpage>1913</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiv392</pub-id><?supplied-pmid 26198719?><pub-id pub-id-type="pmid">26198719</pub-id></element-citation></ref><ref id="CR12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>CN</given-names></name><name><surname>Lin</surname><given-names>CP</given-names></name><name><surname>Huang</surname><given-names>KK</given-names></name><name><surname>Chen</surname><given-names>WC</given-names></name><name><surname>Hsieh</surname><given-names>HP</given-names></name><name><surname>Liang</surname><given-names>PH</given-names></name><name><surname>Hsu</surname><given-names>JT</given-names></name></person-group><article-title>Inhibition of SARS-CoV 3C-like protease activity by theaflavin-3,3&#x02032;-digallate (TF3)</article-title><source>Evid Based Complement Alternat Med</source><year>2005</year><volume>2</volume><issue>2</issue><fpage>209</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1093/ecam/neh081</pub-id><pub-id pub-id-type="pmid">15937562</pub-id></element-citation></ref><ref id="CR13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>N</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Dong</surname><given-names>X</given-names></name><name><surname>Qu</surname><given-names>J</given-names></name><name><surname>Gong</surname><given-names>F</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Qiu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Xia</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name></person-group><article-title>Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study</article-title><source>Lancet</source><year>2020</year><volume>395</volume><issue>10223</issue><fpage>507</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30211-7</pub-id><?supplied-pmid 7135076?><pub-id pub-id-type="pmid">32007143</pub-id></element-citation></ref><ref id="CR14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>PW</given-names></name><name><surname>Ng</surname><given-names>LT</given-names></name><name><surname>Chiang</surname><given-names>LC</given-names></name><name><surname>Lin</surname><given-names>CC</given-names></name></person-group><article-title>Antiviral effects of saikosaponins on human coronavirus 229E in vitro</article-title><source>Clin Exp Pharmacol Physiol</source><year>2006</year><volume>33</volume><issue>7</issue><fpage>612</fpage><lpage>616</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1681.2006.04415.x</pub-id><pub-id pub-id-type="pmid">16789928</pub-id></element-citation></ref><ref id="CR15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>KW</given-names></name><name><surname>Cheng</surname><given-names>SC</given-names></name><name><surname>Chen</surname><given-names>WY</given-names></name><name><surname>Lin</surname><given-names>MH</given-names></name><name><surname>Chuang</surname><given-names>SJ</given-names></name><name><surname>Cheng</surname><given-names>IH</given-names></name><name><surname>Sun</surname><given-names>CY</given-names></name><name><surname>Chou</surname><given-names>CY</given-names></name></person-group><article-title>Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus</article-title><source>Antivir Res</source><year>2015</year><volume>115</volume><fpage>9</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2014.12.011</pub-id><?supplied-pmid 25542975?><pub-id pub-id-type="pmid">25542975</pub-id></element-citation></ref><ref id="CR16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiou</surname><given-names>HE</given-names></name><name><surname>Liu</surname><given-names>CL</given-names></name><name><surname>Buttrey</surname><given-names>MJ</given-names></name><name><surname>Kuo</surname><given-names>HP</given-names></name><name><surname>Liu</surname><given-names>HW</given-names></name><name><surname>Kuo</surname><given-names>HT</given-names></name><name><surname>Lu</surname><given-names>YT</given-names></name></person-group><article-title>Adverse effects of ribavirin and outcome in severe acute respiratory syndrome: experience in two medical centers</article-title><source>Chest</source><year>2005</year><volume>128</volume><issue>1</issue><fpage>263</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1378/chest.128.1.263</pub-id><pub-id pub-id-type="pmid">16002945</pub-id></element-citation></ref><ref id="CR17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>JG</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Hwang</surname><given-names>YH</given-names></name><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Cho</surname><given-names>WK</given-names></name><name><surname>Ma</surname><given-names>JY</given-names></name></person-group><article-title><italic>Eupatorium fortunei</italic> and its components increase antiviral immune responses against RNA viruses</article-title><source>Front Pharmacol</source><year>2017</year><volume>8</volume><fpage>511</fpage><pub-id pub-id-type="doi">10.3389/fphar.2017.00511</pub-id><?supplied-pmid 28824435?><pub-id pub-id-type="pmid">28824435</pub-id></element-citation></ref><ref id="CR18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>CM</given-names></name><name><surname>Cheng</surname><given-names>VC</given-names></name><name><surname>Hung</surname><given-names>IF</given-names></name><name><surname>Wong</surname><given-names>MM</given-names></name><name><surname>Chan</surname><given-names>KH</given-names></name><name><surname>Chan</surname><given-names>KS</given-names></name><name><surname>Kao</surname><given-names>RY</given-names></name><name><surname>Poon</surname><given-names>LL</given-names></name><name><surname>Wong</surname><given-names>CL</given-names></name><name><surname>Guan</surname><given-names>Y</given-names></name><name><surname>Peiris</surname><given-names>JS</given-names></name><name><surname>Yuen</surname><given-names>KY</given-names></name><collab>HKU/UCH SARS Study Group</collab></person-group><article-title>Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings</article-title><source>Thorax</source><year>2004</year><volume>59</volume><issue>3</issue><fpage>252</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1136/thorax.2003.012658</pub-id><pub-id pub-id-type="pmid">14985565</pub-id></element-citation></ref><ref id="CR19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cinatl</surname><given-names>J</given-names></name><name><surname>Morgenstern</surname><given-names>B</given-names></name><name><surname>Bauer</surname><given-names>G</given-names></name><name><surname>Chandra</surname><given-names>P</given-names></name><name><surname>Rabenau</surname><given-names>H</given-names></name><name><surname>Doerr</surname><given-names>HW</given-names></name></person-group><article-title>Treatment of SARS with human interferons</article-title><source>Lancet</source><year>2003</year><volume>362</volume><issue>9380</issue><fpage>293</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(03)13973-6</pub-id><pub-id pub-id-type="pmid">12892961</pub-id></element-citation></ref><ref id="CR20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dyall</surname><given-names>J</given-names></name><name><surname>Coleman</surname><given-names>CM</given-names></name><name><surname>Hart</surname><given-names>BJ</given-names></name><name><surname>Venkataraman</surname><given-names>T</given-names></name><name><surname>Holbrook</surname><given-names>MR</given-names></name><name><surname>Kindrachuk</surname><given-names>J</given-names></name><name><surname>Johnson</surname><given-names>RF</given-names></name><name><surname>Olinger</surname><given-names>GG</given-names><suffix>Jr</suffix></name><name><surname>Jahrling</surname><given-names>PB</given-names></name><name><surname>Laidlaw</surname><given-names>M</given-names></name><name><surname>Johansen</surname><given-names>LM</given-names></name><name><surname>Lear-Rooney</surname><given-names>CM</given-names></name><name><surname>Glass</surname><given-names>PJ</given-names></name><name><surname>Hensley</surname><given-names>LE</given-names></name><name><surname>Frieman</surname><given-names>MB</given-names></name></person-group><article-title>Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection</article-title><source>Antimicrob Agents Chemother</source><year>2014</year><volume>58</volume><issue>8</issue><fpage>4885</fpage><lpage>4893</lpage><pub-id pub-id-type="doi">10.1128/AAC.03036-14</pub-id><?supplied-pmid 24841273?><pub-id pub-id-type="pmid">24841273</pub-id></element-citation></ref><ref id="CR21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dyall</surname><given-names>J</given-names></name><name><surname>Gross</surname><given-names>R</given-names></name><name><surname>Kindrachuk</surname><given-names>J</given-names></name><name><surname>Johnson</surname><given-names>RF</given-names></name><name><surname>Olinger</surname><given-names>GG</given-names><suffix>Jr</suffix></name><name><surname>Hensley</surname><given-names>LE</given-names></name><name><surname>Frieman</surname><given-names>MB</given-names></name><name><surname>Jahrling</surname><given-names>PB</given-names></name></person-group><article-title>Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: current therapeutic options and potential targets for novel therapies</article-title><source>Drugs</source><year>2017</year><volume>77</volume><issue>18</issue><fpage>1935</fpage><lpage>1966</lpage><pub-id pub-id-type="doi">10.1007/s40265-017-0830-1</pub-id><?supplied-pmid 29143192?><pub-id pub-id-type="pmid">29143192</pub-id></element-citation></ref><ref id="CR22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falzarano</surname><given-names>D</given-names></name><name><surname>de Wit</surname><given-names>E</given-names></name><name><surname>Rasmussen</surname><given-names>AL</given-names></name><name><surname>Feldmann</surname><given-names>F</given-names></name><name><surname>Okumura</surname><given-names>A</given-names></name><name><surname>Scott</surname><given-names>DP</given-names></name><name><surname>Brining</surname><given-names>D</given-names></name><name><surname>Bushmaker</surname><given-names>T</given-names></name><name><surname>Martellaro</surname><given-names>C</given-names></name><name><surname>Baseler</surname><given-names>L</given-names></name><name><surname>Benecke</surname><given-names>AG</given-names></name><name><surname>Katze</surname><given-names>MG</given-names></name><name><surname>Munster</surname><given-names>VJ</given-names></name><name><surname>Feldmann</surname><given-names>H</given-names></name></person-group><article-title>Treatment with interferon-&#x003b1;2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques</article-title><source>Nat Med</source><year>2013</year><volume>19</volume><issue>10</issue><fpage>1313</fpage><lpage>1317</lpage><pub-id pub-id-type="doi">10.1038/nm.3362</pub-id><?supplied-pmid 24013700?><pub-id pub-id-type="pmid">24013700</pub-id></element-citation></ref><ref id="CR23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hart</surname><given-names>BJ</given-names></name><name><surname>Dyall</surname><given-names>J</given-names></name><name><surname>Postnikova</surname><given-names>E</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Kindrachuk</surname><given-names>J</given-names></name><name><surname>Johnson</surname><given-names>RF</given-names></name><name><surname>Olinger</surname><given-names>GG</given-names><suffix>Jr</suffix></name><name><surname>Frieman</surname><given-names>MB</given-names></name><name><surname>Holbrook</surname><given-names>MR</given-names></name><name><surname>Jahrling</surname><given-names>PB</given-names></name><name><surname>Hensley</surname><given-names>L</given-names></name></person-group><article-title>Interferon-&#x003b2; and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays</article-title><source>J Gen Virol</source><year>2014</year><volume>95</volume><issue>Pt 3</issue><fpage>571</fpage><lpage>577</lpage><pub-id pub-id-type="doi">10.1099/vir.0.061911-0</pub-id><?supplied-pmid 24323636?><pub-id pub-id-type="pmid">24323636</pub-id></element-citation></ref><ref id="CR24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>TY</given-names></name><name><surname>Wu</surname><given-names>SL</given-names></name><name><surname>Chen</surname><given-names>JC</given-names></name><name><surname>Li</surname><given-names>CC</given-names></name><name><surname>Hsiang</surname><given-names>CY</given-names></name></person-group><article-title>Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction</article-title><source>Antivir Res</source><year>2007</year><volume>74</volume><issue>2</issue><fpage>92</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2006.04.014</pub-id><pub-id pub-id-type="pmid">16730806</pub-id></element-citation></ref><ref id="CR25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Ren</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Fan</surname><given-names>G</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Gu</surname><given-names>X</given-names></name><name><surname>Cheng</surname><given-names>Z</given-names></name><name><surname>Yu</surname><given-names>T</given-names></name><name><surname>Xia</surname><given-names>J</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Xie</surname><given-names>X</given-names></name><name><surname>Yin</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Jiang</surname><given-names>R</given-names></name><name><surname>Gao</surname><given-names>Z</given-names></name><name><surname>Jin</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>B</given-names></name></person-group><article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title><source>Lancet</source><year>2020</year><volume>395</volume><issue>10223</issue><fpage>497</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30183-5</pub-id><?supplied-pmid 31986264?><pub-id pub-id-type="pmid">31986264</pub-id></element-citation></ref><ref id="CR26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hui</surname><given-names>DSC</given-names></name><name><surname>Zumla</surname><given-names>A</given-names></name></person-group><article-title>Severe Acute Respiratory Syndrome: historical, epidemiologic, and clinical features</article-title><source>Infect Dis Clin North Am</source><year>2019</year><volume>33</volume><issue>4</issue><fpage>869</fpage><lpage>889</lpage><pub-id pub-id-type="doi">10.1016/j.idc.2019.07.001</pub-id><?supplied-pmid 31668196?><pub-id pub-id-type="pmid">31668196</pub-id></element-citation></ref><ref id="CR27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>HY</given-names></name><name><surname>Shin</surname><given-names>HS</given-names></name><name><surname>Park</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>YC</given-names></name><name><surname>Yun</surname><given-names>YG</given-names></name><name><surname>Park</surname><given-names>S</given-names></name><name><surname>Shin</surname><given-names>HJ</given-names></name><name><surname>Kim</surname><given-names>K</given-names></name></person-group><article-title>In vitro inhibition of coronavirus replications by the traditionally used medicinal herbal extracts, <italic>Cimicifuga rhizoma</italic>, <italic>Meliae cortex</italic>, <italic>Coptidis rhizoma</italic>, and <italic>Phellodendron cortex</italic></article-title><source>J Clin Virol</source><year>2008</year><volume>41</volume><issue>2</issue><fpage>122</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1016/j.jcv.2007.10.011</pub-id><pub-id pub-id-type="pmid">18036887</pub-id></element-citation></ref><ref id="CR28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>HY</given-names></name><name><surname>Eo</surname><given-names>EY</given-names></name><name><surname>Park</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>YC</given-names></name><name><surname>Park</surname><given-names>S</given-names></name><name><surname>Shin</surname><given-names>HJ</given-names></name><name><surname>Kim</surname><given-names>K</given-names></name></person-group><article-title>Medicinal herbal extracts of Sophorae radix, Acanthopanacis cortex, Sanguisorbae radix and Torilis fructus inhibit coronavirus replication in vitro</article-title><source>Antivir Ther</source><year>2010</year><volume>15</volume><issue>5</issue><fpage>697</fpage><lpage>709</lpage><pub-id pub-id-type="doi">10.3851/IMP1615</pub-id><?supplied-pmid 20710051?><pub-id pub-id-type="pmid">20710051</pub-id></element-citation></ref><ref id="CR29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>UJ</given-names></name><name><surname>Won</surname><given-names>EJ</given-names></name><name><surname>Kee</surname><given-names>SJ</given-names></name><name><surname>Jung</surname><given-names>SI</given-names></name><name><surname>Jang</surname><given-names>HC</given-names></name></person-group><article-title>Combination therapy with lopinavir/ritonavir, ribavirin and interferon-&#x003b1; for Middle East respiratory syndrome</article-title><source>Antivir Ther</source><year>2016</year><volume>21</volume><issue>5</issue><fpage>455</fpage><lpage>459</lpage><pub-id pub-id-type="doi">10.3851/IMP3002</pub-id><?supplied-pmid 26492219?><pub-id pub-id-type="pmid">26492219</pub-id></element-citation></ref><ref id="CR30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kindrachuk</surname><given-names>J</given-names></name><name><surname>Ork</surname><given-names>B</given-names></name><name><surname>Hart</surname><given-names>BJ</given-names></name><name><surname>Mazur</surname><given-names>S</given-names></name><name><surname>Holbrook</surname><given-names>MR</given-names></name><name><surname>Frieman</surname><given-names>MB</given-names></name><name><surname>Traynor</surname><given-names>D</given-names></name><name><surname>Johnson</surname><given-names>RF</given-names></name><name><surname>Dyall</surname><given-names>J</given-names></name><name><surname>Kuhn</surname><given-names>JH</given-names></name><name><surname>Olinger</surname><given-names>GG</given-names></name><name><surname>Hensley</surname><given-names>LE</given-names></name><name><surname>Jahrling</surname><given-names>PB</given-names></name></person-group><article-title>Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis</article-title><source>Antimicrob Agents Chemother</source><year>2015</year><volume>59</volume><issue>2</issue><fpage>1088</fpage><lpage>1099</lpage><pub-id pub-id-type="doi">10.1128/AAC.03659-14</pub-id><?supplied-pmid 25487801?><pub-id pub-id-type="pmid">25487801</pub-id></element-citation></ref><ref id="CR31"><mixed-citation publication-type="other">Kumar S, Maurya VK, Prasad AK, Bhatt ML, Saxena SK (2020) Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV). Virus Dis:1&#x02013;9. 10.1007/s13337-020-00571-5</mixed-citation></ref><ref id="CR32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leong</surname><given-names>HN</given-names></name><name><surname>Ang</surname><given-names>B</given-names></name><name><surname>Earnest</surname><given-names>A</given-names></name><name><surname>Teoh</surname><given-names>C</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Leo</surname><given-names>YS</given-names></name></person-group><article-title>Investigational use of ribavirin in the treatment of severe acute respiratory syndrome, Singapore, 2003</article-title><source>Tropical Med Int Health</source><year>2004</year><volume>9</volume><issue>8</issue><fpage>923</fpage><lpage>927</lpage><pub-id pub-id-type="doi">10.1111/j.1365-3156.2004.01281.x</pub-id></element-citation></ref><ref id="CR33"><mixed-citation publication-type="other">Li G, De Clercq E (2020) Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 10.1038/d41573-020-00016-0</mixed-citation></ref><ref id="CR34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>SY</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>HQ</given-names></name><name><surname>Guo</surname><given-names>HY</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Hua</surname><given-names>SN</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Xiao</surname><given-names>PG</given-names></name><name><surname>Li</surname><given-names>RS</given-names></name><name><surname>Tan</surname><given-names>X</given-names></name></person-group><article-title>Identification of natural compounds with antiviral activities against SARS-associated coronavirus</article-title><source>Antivir Res</source><year>2005</year><volume>67</volume><issue>1</issue><fpage>18</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2005.02.007</pub-id><pub-id pub-id-type="pmid">15885816</pub-id></element-citation></ref><ref id="CR35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Guan</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Tong</surname><given-names>Y</given-names></name><name><surname>Ren</surname><given-names>R</given-names></name><name><surname>Leung</surname><given-names>KSM</given-names></name><name><surname>Lau</surname><given-names>EHY</given-names></name><name><surname>Wong</surname><given-names>JY</given-names></name><name><surname>Xing</surname><given-names>X</given-names></name><name><surname>Xiang</surname><given-names>N</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Tu</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Jin</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Shao</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Tao</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Deng</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Ma</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>G</given-names></name><name><surname>Lam</surname><given-names>TTY</given-names></name><name><surname>Wu</surname><given-names>JTK</given-names></name><name><surname>Gao</surname><given-names>GF</given-names></name><name><surname>Cowling</surname><given-names>BJ</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Leung</surname><given-names>GM</given-names></name><name><surname>Feng</surname><given-names>Z</given-names></name></person-group><article-title>Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia</article-title><source>N Engl J Med</source><year>2020</year><volume>382</volume><fpage>1199</fpage><lpage>1207</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2001316</pub-id><?supplied-pmid 31995857?><pub-id pub-id-type="pmid">31995857</pub-id></element-citation></ref><ref id="CR36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loutfy</surname><given-names>MR</given-names></name><name><surname>Blatt</surname><given-names>LM</given-names></name><name><surname>Siminovitch</surname><given-names>KA</given-names></name><name><surname>Ward</surname><given-names>S</given-names></name><name><surname>Wolff</surname><given-names>B</given-names></name><name><surname>Lho</surname><given-names>H</given-names></name><name><surname>Pham</surname><given-names>DH</given-names></name><name><surname>Deif</surname><given-names>H</given-names></name><name><surname>LaMere</surname><given-names>EA</given-names></name><name><surname>Chang</surname><given-names>M</given-names></name><name><surname>Kain</surname><given-names>KC</given-names></name><name><surname>Farcas</surname><given-names>GA</given-names></name><name><surname>Ferguson</surname><given-names>P</given-names></name><name><surname>Latchford</surname><given-names>M</given-names></name><name><surname>Levy</surname><given-names>G</given-names></name><name><surname>Dennis</surname><given-names>JW</given-names></name><name><surname>Lai</surname><given-names>EK</given-names></name><name><surname>Fish</surname><given-names>EN</given-names></name></person-group><article-title>Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study</article-title><source>JAMA</source><year>2003</year><volume>290</volume><issue>24</issue><fpage>3222</fpage><lpage>3228</lpage><pub-id pub-id-type="doi">10.1001/jama.290.24.3222</pub-id><pub-id pub-id-type="pmid">14693875</pub-id></element-citation></ref><ref id="CR37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muller</surname><given-names>MP</given-names></name><name><surname>Dresser</surname><given-names>L</given-names></name><name><surname>Raboud</surname><given-names>J</given-names></name><name><surname>McGeer</surname><given-names>A</given-names></name><name><surname>Rea</surname><given-names>E</given-names></name><name><surname>Richardson</surname><given-names>SE</given-names></name><name><surname>Mazzulli</surname><given-names>T</given-names></name><name><surname>Loeb</surname><given-names>M</given-names></name><name><surname>Louie</surname><given-names>M</given-names></name><collab>Canadian SARS Research Network</collab></person-group><article-title>Adverse events associated with high-dose ribavirin: evidence from the Toronto outbreak of severe acute respiratory syndrome</article-title><source>Pharmacotherapy</source><year>2007</year><volume>27</volume><issue>4</issue><fpage>494</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1592/phco.27.4.494</pub-id><pub-id pub-id-type="pmid">17381375</pub-id></element-citation></ref><ref id="CR38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Keefe</surname><given-names>BR</given-names></name><name><surname>Giomarelli</surname><given-names>B</given-names></name><name><surname>Barnard</surname><given-names>DL</given-names></name><name><surname>Shenoy</surname><given-names>SR</given-names></name><name><surname>Chan</surname><given-names>PK</given-names></name><name><surname>McMahon</surname><given-names>JB</given-names></name><name><surname>Palmer</surname><given-names>KE</given-names></name><name><surname>Barnett</surname><given-names>BW</given-names></name><name><surname>Meyerholz</surname><given-names>DK</given-names></name><name><surname>Wohlford-Lenane</surname><given-names>CL</given-names></name><name><surname>McCray</surname><given-names>PB</given-names><suffix>Jr</suffix></name></person-group><article-title>Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family Coronaviridae</article-title><source>J Virol</source><year>2010</year><volume>84</volume><issue>5</issue><fpage>2511</fpage><lpage>2521</lpage><pub-id pub-id-type="doi">10.1128/JVI.02322-09</pub-id><?supplied-pmid 20032190?><pub-id pub-id-type="pmid">20032190</pub-id></element-citation></ref><ref id="CR39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Omrani</surname><given-names>AS</given-names></name><name><surname>Saad</surname><given-names>MM</given-names></name><name><surname>Baig</surname><given-names>K</given-names></name><name><surname>Bahloul</surname><given-names>A</given-names></name><name><surname>Abdul-Matin</surname><given-names>M</given-names></name><name><surname>Alaidaroos</surname><given-names>AY</given-names></name><name><surname>Almakhlafi</surname><given-names>GA</given-names></name><name><surname>Albarrak</surname><given-names>MM</given-names></name><name><surname>Memish</surname><given-names>ZA</given-names></name><name><surname>Albarrak</surname><given-names>AM</given-names></name></person-group><article-title>Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study</article-title><source>Lancet Infect Dis</source><year>2014</year><volume>14</volume><issue>11</issue><fpage>1090</fpage><lpage>1095</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(14)70920-X</pub-id><?supplied-pmid 25278221?><pub-id pub-id-type="pmid">25278221</pub-id></element-citation></ref><ref id="CR40"><mixed-citation publication-type="other">Paules CI, Marston HD, Fauci AS (2020) Coronavirus infections-more than just the common cold. JAMA. 10.1001/jama.2020.0757. [Epub ahead of print]</mixed-citation></ref><ref id="CR41"><mixed-citation publication-type="other">PIB Delhi (2020) Advisory for corona virus. Homoeopathy for prevention of corona virus Infections. unani medicines useful in symptomatic management of corona virus infection. Posted on: 29 Jan 2020 10:29 AM by PIB Delhi. <ext-link ext-link-type="uri" xlink:href="https://pib.gov.in/PressReleasePage.aspx?PRID=1600895">https://pib.gov.in/PressReleasePage.aspx?PRID=1600895</ext-link></mixed-citation></ref><ref id="CR42"><mixed-citation publication-type="other">ProMED-mail (2020) Novel coronavirus (32): China, global, case management, research. <ext-link ext-link-type="uri" xlink:href="https://promedmail.org/">https://promedmail.org/</ext-link>. Accessed 20 Mar 2020</mixed-citation></ref><ref id="CR43"><mixed-citation publication-type="other">Rasmussen SA, Watson AK, Swerdlow DL (2016) Middle East Respiratory Syndrome (MERS). Microbiol Spectr 4(3). 10.1128/microbiolspec.EI10-0020-2016</mixed-citation></ref><ref id="CR44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saijo</surname><given-names>M</given-names></name><name><surname>Morikawa</surname><given-names>S</given-names></name><name><surname>Fukushi</surname><given-names>S</given-names></name><name><surname>Mizutani</surname><given-names>T</given-names></name><name><surname>Hasegawa</surname><given-names>H</given-names></name><name><surname>Nagata</surname><given-names>N</given-names></name><name><surname>Iwata</surname><given-names>N</given-names></name><name><surname>Kurane</surname><given-names>I</given-names></name></person-group><article-title>Inhibitory effect of mizoribine and ribavirin on the replication of severe acute respiratory syndrome (SARS)-associated coronavirus</article-title><source>Antivir Res</source><year>2005</year><volume>66</volume><issue>2&#x02013;3</issue><fpage>159</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2005.01.003</pub-id><pub-id pub-id-type="pmid">15911031</pub-id></element-citation></ref><ref id="CR45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saxena</surname><given-names>SK</given-names></name><name><surname>Haikerwal</surname><given-names>A</given-names></name><name><surname>Gadugu</surname><given-names>S</given-names></name><name><surname>Bhatt</surname><given-names>ML</given-names></name></person-group><article-title>Complementary and alternative medicine in alliance with conventional medicine for dengue therapeutics and prevention</article-title><source>Future Virol</source><year>2017</year><volume>12</volume><issue>8</issue><fpage>399</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.2217/fvl-2017-0047</pub-id></element-citation></ref><ref id="CR46"><mixed-citation publication-type="other">Schindewolf C, Menachery VD (2019) Middle East respiratory syndrome vaccine candidates: cautious optimism. Viruses 11(1). pii: E74. 10.3390/v11010074</mixed-citation></ref><ref id="CR47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shahani</surname><given-names>L</given-names></name><name><surname>Ariza-Heredia</surname><given-names>EJ</given-names></name><name><surname>Chemaly</surname><given-names>RF</given-names></name></person-group><article-title>Antiviral therapy for respiratory viral infections in immunocompromised patients</article-title><source>Expert Rev Anti-Infect Ther</source><year>2017</year><volume>15</volume><issue>4</issue><fpage>401</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.1080/14787210.2017.1279970</pub-id><?supplied-pmid 28067078?><pub-id pub-id-type="pmid">28067078</pub-id></element-citation></ref><ref id="CR48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheahan</surname><given-names>TP</given-names></name><name><surname>Sims</surname><given-names>AC</given-names></name><name><surname>Leist</surname><given-names>SR</given-names></name><name><surname>Sch&#x000e4;fer</surname><given-names>A</given-names></name><name><surname>Won</surname><given-names>J</given-names></name><name><surname>Brown</surname><given-names>AJ</given-names></name><name><surname>Montgomery</surname><given-names>SA</given-names></name><name><surname>Hogg</surname><given-names>A</given-names></name><name><surname>Babusis</surname><given-names>D</given-names></name><name><surname>Clarke</surname><given-names>MO</given-names></name><name><surname>Spahn</surname><given-names>JE</given-names></name><name><surname>Bauer</surname><given-names>L</given-names></name><name><surname>Sellers</surname><given-names>S</given-names></name><name><surname>Porter</surname><given-names>D</given-names></name><name><surname>Feng</surname><given-names>JY</given-names></name><name><surname>Cihlar</surname><given-names>T</given-names></name><name><surname>Jordan</surname><given-names>R</given-names></name><name><surname>Denison</surname><given-names>MR</given-names></name><name><surname>Baric</surname><given-names>RS</given-names></name></person-group><article-title>Comparative therapeutic efficacy of Remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV</article-title><source>Nat Commun</source><year>2020</year><volume>11</volume><issue>1</issue><fpage>222</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-13940-6</pub-id><?supplied-pmid 31924756?><pub-id pub-id-type="pmid">31924756</pub-id></element-citation></ref><ref id="CR49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shehata</surname><given-names>MM</given-names></name><name><surname>Gomaa</surname><given-names>MR</given-names></name><name><surname>Ali</surname><given-names>MA</given-names></name><name><surname>Kayali</surname><given-names>G</given-names></name></person-group><article-title>Middle East respiratory syndrome coronavirus: a comprehensive review</article-title><source>Front Med</source><year>2016</year><volume>10</volume><issue>2</issue><fpage>120</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1007/s11684-016-0430-6</pub-id><?supplied-pmid 26791756?><pub-id pub-id-type="pmid">26791756</pub-id></element-citation></ref><ref id="CR50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skariyachan</surname><given-names>S</given-names></name><name><surname>Challapilli</surname><given-names>SB</given-names></name><name><surname>Packirisamy</surname><given-names>S</given-names></name><name><surname>Kumargowda</surname><given-names>ST</given-names></name><name><surname>Sridhar</surname><given-names>VS</given-names></name></person-group><article-title>Recent aspects on the pathogenesis mechanism, animal models and novel therapeutic interventions for Middle East respiratory syndrome coronavirus infections</article-title><source>Front Microbiol</source><year>2019</year><volume>10</volume><fpage>569</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2019.00569</pub-id><?supplied-pmid 30984127?><pub-id pub-id-type="pmid">30984127</pub-id></element-citation></ref><ref id="CR51"><mixed-citation publication-type="other">Song Z, Xu Y, Bao L, Zhang L, Yu P, Qu Y, Zhu H, Zhao W, Han Y, Qin C (2019) From SARS to MERS, thrusting coronaviruses into the spotlight. Viruses 11(1). pii: E59. 10.3390/v11010059</mixed-citation></ref><ref id="CR52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spanakis</surname><given-names>N</given-names></name><name><surname>Tsiodras</surname><given-names>S</given-names></name><name><surname>Haagmans</surname><given-names>BL</given-names></name><name><surname>Raj</surname><given-names>VS</given-names></name><name><surname>Pontikis</surname><given-names>K</given-names></name><name><surname>Koutsoukou</surname><given-names>A</given-names></name><name><surname>Koulouris</surname><given-names>NG</given-names></name><name><surname>Osterhaus</surname><given-names>AD</given-names></name><name><surname>Koopmans</surname><given-names>MP</given-names></name><name><surname>Tsakris</surname><given-names>A</given-names></name></person-group><article-title>Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen</article-title><source>Int J Antimicrob Agents</source><year>2014</year><volume>44</volume><issue>6</issue><fpage>528</fpage><lpage>532</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2014.07.026</pub-id><?supplied-pmid 25288266?><pub-id pub-id-type="pmid">25288266</pub-id></element-citation></ref><ref id="CR53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Totura</surname><given-names>AL</given-names></name><name><surname>Bavari</surname><given-names>S</given-names></name></person-group><article-title>Broad-spectrum coronavirus antiviral drug discovery</article-title><source>Expert Opin Drug Discov</source><year>2019</year><volume>14</volume><issue>4</issue><fpage>397</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1080/17460441.2019.1581171</pub-id><?supplied-pmid 30849247?><pub-id pub-id-type="pmid">30849247</pub-id></element-citation></ref><ref id="CR54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ulasli</surname><given-names>M</given-names></name><name><surname>Gurses</surname><given-names>SA</given-names></name><name><surname>Bayraktar</surname><given-names>R</given-names></name><name><surname>Yumrutas</surname><given-names>O</given-names></name><name><surname>Oztuzcu</surname><given-names>S</given-names></name><name><surname>Igci</surname><given-names>M</given-names></name><name><surname>Igci</surname><given-names>YZ</given-names></name><name><surname>Cakmak</surname><given-names>EA</given-names></name><name><surname>Arslan</surname><given-names>A</given-names></name></person-group><article-title>The effects of Nigella sativa (Ns), Anthemis hyalina (Ah) and Citrus sinensis (Cs) extracts on the replication of coronavirus and the expression of TRP genes family</article-title><source>Mol Biol Rep</source><year>2014</year><volume>41</volume><issue>3</issue><fpage>1703</fpage><lpage>1711</lpage><pub-id pub-id-type="doi">10.1007/s11033-014-3019-7</pub-id><?supplied-pmid 24413991?><pub-id pub-id-type="pmid">24413991</pub-id></element-citation></ref><ref id="CR55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Wong</surname><given-names>G</given-names></name><name><surname>Lu</surname><given-names>G</given-names></name><name><surname>Yan</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>GF</given-names></name></person-group><article-title>MERS-CoV spike protein: targets for vaccines and therapeutics</article-title><source>Antivir Res</source><year>2016</year><volume>133</volume><fpage>165</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2016.07.015</pub-id><?supplied-pmid 27468951?><pub-id pub-id-type="pmid">27468951</pub-id></element-citation></ref><ref id="CR56"><mixed-citation publication-type="other">Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G (2020) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 10.1038/s41422-020-0282-0. [Epub ahead of print]</mixed-citation></ref><ref id="CR57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ward</surname><given-names>SE</given-names></name><name><surname>Loutfy</surname><given-names>MR</given-names></name><name><surname>Blatt</surname><given-names>LM</given-names></name><name><surname>Siminovitch</surname><given-names>KA</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Hinek</surname><given-names>A</given-names></name><name><surname>Wolff</surname><given-names>B</given-names></name><name><surname>Pham</surname><given-names>DH</given-names></name><name><surname>Deif</surname><given-names>H</given-names></name><name><surname>LaMere</surname><given-names>EA</given-names></name><name><surname>Kain</surname><given-names>KC</given-names></name><name><surname>Farcas</surname><given-names>GA</given-names></name><name><surname>Ferguson</surname><given-names>P</given-names></name><name><surname>Latchford</surname><given-names>M</given-names></name><name><surname>Levy</surname><given-names>G</given-names></name><name><surname>Fung</surname><given-names>L</given-names></name><name><surname>Dennis</surname><given-names>JW</given-names></name><name><surname>Lai</surname><given-names>EK</given-names></name><name><surname>Fish</surname><given-names>EN</given-names></name></person-group><article-title>Dynamic changes in clinical features and cytokine/chemokine responses in SARS patients treated with interferon alfacon-1 plus corticosteroids</article-title><source>Antivir Ther</source><year>2005</year><volume>10</volume><issue>2</issue><fpage>263</fpage><lpage>275</lpage><?supplied-pmid 15865221?><pub-id pub-id-type="pmid">15865221</pub-id></element-citation></ref><ref id="CR58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warren</surname><given-names>TK</given-names></name><name><surname>Wells</surname><given-names>J</given-names></name><name><surname>Panchal</surname><given-names>RG</given-names></name><name><surname>Stuthman</surname><given-names>KS</given-names></name><name><surname>Garza</surname><given-names>NL</given-names></name><name><surname>Van Tongeren</surname><given-names>SA</given-names></name><name><surname>Dong</surname><given-names>L</given-names></name><name><surname>Retterer</surname><given-names>CJ</given-names></name><name><surname>Eaton</surname><given-names>BP</given-names></name><name><surname>Pegoraro</surname><given-names>G</given-names></name><name><surname>Honnold</surname><given-names>S</given-names></name><name><surname>Bantia</surname><given-names>S</given-names></name><name><surname>Kotian</surname><given-names>P</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Taubenheim</surname><given-names>BR</given-names></name><name><surname>Welch</surname><given-names>LS</given-names></name><name><surname>Minning</surname><given-names>DM</given-names></name><name><surname>Babu</surname><given-names>YS</given-names></name><name><surname>Sheridan</surname><given-names>WP</given-names></name><name><surname>Bavari</surname><given-names>S</given-names></name></person-group><article-title>Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430</article-title><source>Nature</source><year>2014</year><volume>508</volume><issue>7496</issue><fpage>402</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1038/nature13027</pub-id><?supplied-pmid 24590073?><pub-id pub-id-type="pmid">24590073</pub-id></element-citation></ref><ref id="CR59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Wilde</surname><given-names>AH</given-names></name><name><surname>Zevenhoven-Dobbe</surname><given-names>JC</given-names></name><name><surname>van der Meer</surname><given-names>Y</given-names></name><name><surname>Thiel</surname><given-names>V</given-names></name><name><surname>Narayanan</surname><given-names>K</given-names></name><name><surname>Makino</surname><given-names>S</given-names></name><name><surname>Snijder</surname><given-names>EJ</given-names></name><name><surname>van Hemert</surname><given-names>MJ</given-names></name></person-group><article-title>Cyclosporin A inhibits the replication of diverse coronaviruses</article-title><source>J Gen Virol</source><year>2011</year><volume>92</volume><issue>Pt 11</issue><fpage>2542</fpage><lpage>2548</lpage><pub-id pub-id-type="doi">10.1099/vir.0.034983-0</pub-id><?supplied-pmid 21752960?><pub-id pub-id-type="pmid">21752960</pub-id></element-citation></ref><ref id="CR60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Wilde</surname><given-names>AH</given-names></name><name><surname>Jochmans</surname><given-names>D</given-names></name><name><surname>Posthuma</surname><given-names>CC</given-names></name><name><surname>Zevenhoven-Dobbe</surname><given-names>JC</given-names></name><name><surname>van Nieuwkoop</surname><given-names>S</given-names></name><name><surname>Bestebroer</surname><given-names>TM</given-names></name><name><surname>van den Hoogen</surname><given-names>BG</given-names></name><name><surname>Neyts</surname><given-names>J</given-names></name><name><surname>Snijder</surname><given-names>EJ</given-names></name></person-group><article-title>Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture</article-title><source>Antimicrob Agents Chemother</source><year>2014</year><volume>58</volume><issue>8</issue><fpage>4875</fpage><lpage>4884</lpage><pub-id pub-id-type="doi">10.1128/AAC.03011-14</pub-id><?supplied-pmid 24841269?><pub-id pub-id-type="pmid">24841269</pub-id></element-citation></ref><ref id="CR61"><mixed-citation publication-type="other">World Health Organization (2020a) Novel Coronavirus (2019-nCoV) situation report-14. <ext-link ext-link-type="uri" xlink:href="https://www.who.int/docs/default-source/coronaviruse/situationreports/20200203-sitrep-14-ncov.pdf">https://www.who.int/docs/default-source/coronaviruse/situationreports/20200203-sitrep-14-ncov.pdf</ext-link>. Accessed 3 Feb 2020</mixed-citation></ref><ref id="CR62"><mixed-citation publication-type="other">World Health Organization (2020b) Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. Interim guidance. 12 Jan 2020</mixed-citation></ref><ref id="CR63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>K</given-names></name><name><surname>Zhong</surname><given-names>W</given-names></name><name><surname>Cai</surname><given-names>W</given-names></name><name><surname>Yin</surname><given-names>Z</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Deng</surname><given-names>Z</given-names></name><name><surname>Wei</surname><given-names>M</given-names></name><name><surname>Xiong</surname><given-names>J</given-names></name><name><surname>Hawkey</surname><given-names>PM</given-names></name></person-group><article-title>Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China</article-title><source>J Med Microbiol</source><year>2003</year><volume>52</volume><issue>Pt 8</issue><fpage>715</fpage><lpage>720</lpage><pub-id pub-id-type="doi">10.1099/jmm.0.05320-0</pub-id><pub-id pub-id-type="pmid">12867568</pub-id></element-citation></ref><ref id="CR64"><mixed-citation publication-type="other">Zheng J, Hassan S, Alagaili AN, Alshukairi AN, Amor NMS, Mukhtar N, Nazeer IM, Tahir Z, Akhter N, Perlman S, Yaqub T (2019) Middle East Respiratory syndrome coronavirus seropositivity in Camel handlers and their families, Pakistan. Emerg Infect Dis 25(12). 10.3201/eid2512.191169</mixed-citation></ref><ref id="CR65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Vedantham</surname><given-names>P</given-names></name><name><surname>Lu</surname><given-names>K</given-names></name><name><surname>Agudelo</surname><given-names>J</given-names></name><name><surname>Carrion</surname><given-names>R</given-names><suffix>Jr</suffix></name><name><surname>Nunneley</surname><given-names>JW</given-names></name><name><surname>Barnard</surname><given-names>D</given-names></name><name><surname>P&#x000f6;hlmann</surname><given-names>S</given-names></name><name><surname>McKerrow</surname><given-names>JH</given-names></name><name><surname>Renslo</surname><given-names>AR</given-names></name><name><surname>Simmons</surname><given-names>G</given-names></name></person-group><article-title>Protease inhibitors targeting coronavirus and filovirus entry</article-title><source>Antivir Res</source><year>2015</year><volume>116</volume><fpage>76</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2015.01.011</pub-id><?supplied-pmid 25666761?><pub-id pub-id-type="pmid">25666761</pub-id></element-citation></ref></ref-list></back></article>